Making vaccines for mosquito-transmitted viruses ever safer
Live-attenuated viral vaccines represent successful vaccine approaches but come with a risk of reversion or recombination of the vaccine to a virulent form. An important consideration for mosquito-transmitted viruses is that they should not replicate in mosquito vectors to prevent vaccine-derived virulent strains. The EU-funded VIVARNAsilencing2 proof-of-concept project aims to enhance the safety of live-attenuated vaccines for mosquito-transmitted viruses by preventing their replication in mosquitoes. The researchers will exploit a small RNA-based gene regulatory network of the mosquito vector to target viral RNA for degradation. The initial focus will be on the viruses with a large disease burden, such as the dengue virus, Zika virus and chikungunya virus.
Fields of science
Call for proposal
See other projects for this call
Funding SchemeERC-POC-LS - ERC Proof of Concept Lump Sum Pilot
6525 GA Nijmegen